Intellia Therapeutics, Inc.
(NASDAQ : NTLA)

( )
NTLA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.01%167.590.7%$1123.19m
PFEPfizer Inc. -1.18%49.270.9%$913.61m
LLYEli Lilly & Co. 2.11%316.851.1%$810.94m
ABBVAbbVie, Inc. -0.77%141.451.9%$792.28m
MRKMerck & Co., Inc. 0.46%91.010.7%$787.57m
BMYBristol-Myers Squibb Co. 0.57%74.551.0%$638.52m
SIGASIGA Technologies, Inc. 1.85%24.770.0%$466.92m
AZNAstraZeneca Plc -0.48%66.421.0%$364.06m
GBTGlobal Blood Therapeutics, Inc. 0.00%67.005.6%$344.80m
GSKGSK Plc -1.65%34.680.3%$292.03m
ALNYAlnylam Pharmaceuticals, Inc. -2.20%223.138.2%$270.05m
VERUVeru, Inc. 6.88%23.780.0%$243.99m
HZNPHorizon Therapeutics Plc -3.67%61.735.4%$222.09m
CCXIChemoCentryx, Inc. -0.16%50.782.9%$208.38m
KRTXKaruna Therapeutics, Inc. -0.93%261.230.0%$204.24m

Company Profile

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.